MYRIAD GENETICS, INC. Payments to Acquire Debt Securities, Available-for-sale
MYRIAD GENETICS, INC. (MYGN) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2025-02-28
- MYRIAD GENETICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- MYRIAD GENETICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- MYRIAD GENETICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- MYRIAD GENETICS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- MYRIAD GENETICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $0.00.
- MYRIAD GENETICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- MYRIAD GENETICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $103.20M, a 30.18% decline from fiscal 2021.
- MYRIAD GENETICS, INC. payments to acquire debt securities, available-for-sale for fiscal 2021 was $147.80M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-02-28 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $0.00 derived: sum of 2 quarters · filed 2025-02-28 | $0.00 derived: sum of 3 quarters · filed 2025-02-28 | $0.00 10-K · filed 2025-02-28 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 derived: sum of 2 quarters · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | $4.40M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $0.00 10-Q · filed 2023-08-04 | $4.40M derived: sum of 3 quarters · filed 2025-02-28 | $17.70M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $4.40M derived: sum of 2 quarters · filed 2025-02-28 | $17.70M derived: sum of 3 quarters · filed 2025-02-28 | $51.10M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $4.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $17.70M derived: sum of 2 quarters · filed 2025-02-28 | $51.10M derived: sum of 3 quarters · filed 2025-02-28 | $103.20M 10-K · filed 2025-02-28 |
| 2022-09-30 | $13.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $46.70M derived: sum of 2 quarters · filed 2023-11-07 | $98.80M 10-Q · filed 2023-11-07 | $145.60M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $33.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $85.50M 10-Q · filed 2023-08-04 | $132.30M derived: sum of 3 quarters · filed 2024-02-28 | $196.70M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $52.10M 10-Q · filed 2023-05-04 | $98.90M derived: sum of 2 quarters · filed 2024-02-28 | $163.30M derived: sum of 3 quarters · filed 2024-02-28 | $199.90M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $46.80M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $111.20M derived: sum of 2 quarters · filed 2024-02-28 | $147.80M derived: sum of 3 quarters · filed 2024-02-28 | $147.80M 10-K · filed 2024-02-28 |
| 2021-09-30 | $64.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $101.00M derived: sum of 2 quarters · filed 2022-11-02 | $101.00M 10-Q · filed 2022-11-02 | $101.00M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $36.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | $36.60M 10-Q · filed 2022-08-05 | $36.60M derived: sum of 3 quarters · filed 2023-03-01 | $36.60M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-06 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | $0.00 derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $0.00 derived: 10-K 6 month − 10-Q 3 month · filed 2023-03-01 | $0.00 10-K · filed 2023-03-01 | $0.00 derived: sum of 3 quarters · filed 2023-03-01 | $15.80M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2021-08-04 | $15.80M 10-Q · filed 2021-11-04 | $37.70M derived: sum of 4 quarters · filed 2021-08-04 |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $15.80M 10-Q · filed 2021-08-04 | $37.70M derived: sum of 3 quarters · filed 2021-08-04 | $60.80M 10-K · filed 2023-03-01 |
| 2020-03-31 | $15.80M 10-Q · filed 2021-05-05 | $37.70M derived: sum of 2 quarters · filed 2021-05-05 | $60.80M 10-Q · filed 2020-05-06 | $82.30M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $21.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-07 | $45.00M 10-Q · filed 2020-02-07 | $66.50M derived: sum of 3 quarters · filed 2022-02-25 | $86.90M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-09-30 | $23.10M 10-Q · filed 2020-11-09 | $44.60M derived: sum of 2 quarters · filed 2022-02-25 | $65.00M derived: sum of 3 quarters · filed 2022-02-25 | $87.20M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-06-30 | $21.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $41.90M derived: sum of 2 quarters · filed 2022-02-25 | $64.10M derived: sum of 3 quarters · filed 2022-02-25 | $78.50M 10-K · filed 2022-02-25 |
| 2019-03-31 | $20.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-06 | $42.60M derived: sum of 2 quarters · filed 2020-05-06 | $57.00M 10-Q · filed 2020-05-06 | $58.50M derived: sum of 4 quarters · filed 2021-03-16 |
| 2018-12-31 | $22.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-07 | $36.60M 10-Q · filed 2020-02-07 | $38.10M derived: sum of 3 quarters · filed 2021-03-16 | $56.20M derived: sum of 4 quarters · filed 2021-03-16 |
| 2018-09-30 | $14.40M 10-Q · filed 2019-11-06 | $15.90M derived: sum of 2 quarters · filed 2021-03-16 | $34.00M derived: sum of 3 quarters · filed 2021-03-16 | $63.80M derived: sum of 4 quarters · filed 2021-03-16 |
| 2018-06-30 | $1.50M derived: 10-KT 12 month − 10-Q 9 month · filed 2021-03-16 | $19.60M derived: sum of 2 quarters · filed 2021-03-16 | $49.40M derived: sum of 3 quarters · filed 2021-03-16 | $80.90M 10-KT · filed 2021-03-16 |
| 2018-03-31 | $18.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-08 | $47.90M derived: sum of 2 quarters · filed 2019-05-08 | $79.40M 10-Q · filed 2019-05-08 | |
| 2017-12-31 | $29.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-06 | $61.30M 10-Q · filed 2019-02-06 | ||
| 2017-09-30 | $31.50M 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | $87.50M 10-K · filed 2019-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |